flutamide has been researched along with Drug Withdrawal Symptoms in 16 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flutamide withdrawal was undertaken at the time of disease progression." | 1.29 | The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. ( Small, EJ; Srinivas, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (62.50) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suzuki, H | 2 |
| Okihara, K | 1 |
| Miyake, H | 1 |
| Fujisawa, M | 1 |
| Miyoshi, S | 1 |
| Matsumoto, T | 1 |
| Fujii, M | 1 |
| Takihana, Y | 1 |
| Usui, T | 1 |
| Matsuda, T | 1 |
| Ozono, S | 1 |
| Kumon, H | 1 |
| Ichikawa, T | 2 |
| Miki, T | 1 |
| Nayebi, AR | 1 |
| Rezazadeh, H | 1 |
| Terada, N | 1 |
| Shimizu, Y | 1 |
| Yoshida, T | 1 |
| Maeno, A | 1 |
| Kamba, T | 1 |
| Inoue, T | 1 |
| Nakamura, E | 1 |
| Kamoto, T | 1 |
| Ogawa, O | 1 |
| Lee, YF | 1 |
| Lin, WJ | 1 |
| Huang, J | 1 |
| Messing, EM | 1 |
| Chan, FL | 1 |
| Wilding, G | 1 |
| Chang, C | 1 |
| Kojima, S | 1 |
| Akakura, K | 1 |
| Shimbo, M | 1 |
| Ito, H | 1 |
| Sartor, AO | 1 |
| Tangen, CM | 1 |
| Hussain, MH | 1 |
| Eisenberger, MA | 1 |
| Parab, M | 1 |
| Fontana, JA | 1 |
| Chapman, RA | 1 |
| Mills, GM | 1 |
| Raghavan, D | 1 |
| Crawford, ED | 1 |
| Moul, JW | 1 |
| Srivastava, S | 1 |
| McLeod, DG | 1 |
| Kelly, WK | 3 |
| Scher, HI | 3 |
| Morote, J | 1 |
| Lorente, JA | 1 |
| Vallejo, C | 1 |
| Small, EJ | 3 |
| Srinivas, S | 1 |
| Slovin, S | 1 |
| Baron, A | 1 |
| Bok, R | 1 |
| Breul, J | 1 |
| Paul, R | 1 |
| Longmore, L | 1 |
| Foley, JP | 1 |
| Rozanski, TA | 1 |
| Higgins, B | 1 |
| Thompson, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer[NCT01875250] | Phase 2 | 38 participants (Actual) | Interventional | 2013-07-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Normal testosterone is 270-1070 nd/dL. (NCT01875250)
Timeframe: 84 days
| Intervention | ng/dl (Median) |
|---|---|
| All Participants | 834 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01875250)
Timeframe: Date treatment consent signed to date off study, approximately 43 months and 13 days for Arm A, and 78 months and 6 days for Arm B.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 19 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 19 |
Median PSA change would be considered optimal. (NCT01875250)
Timeframe: 84 days
| Intervention | Percent change (Median) |
|---|---|
| Arm A - Enzalutamide for 3 Months | -99 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | -99 |
Growth rate was measured using the growth rate equation -f(t) = exp (-d*t) + exp (g*t) -1 where exp is the base of the natural algorithm, e = 2.7182 and t is days since treatment started. The tumor growth rate equation measures Prostate Specific Antigen (PSA) rise over time. The UOM is unitless because this is a way to measure PSA kinetics. (NCT01875250)
Timeframe: 7 months
| Intervention | unitless (Number) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 0.031 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 0.030 |
VEGF was measured by the enzyme-linked immunosorbent assay (ELISA) assay. The lower limit of quantitation of assay was 9.0 pg/ml. (NCT01875250)
Timeframe: 30 Days After the Start of Course 1 and Course 2 of Enzalutamide
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 192 | 165.04 |
PSA recovery is defined as the return above baseline PSA in participants with normal testosterone and non-metastatic, castration sensitive prostate cancer. (NCT01875250)
Timeframe: up to 41 months
| Intervention | Days (Median) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 224 | 189 |
2 reviews available for flutamide and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Molecular implications of the antiandrogen withdrawal syndrome.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Male; Mutation; Orchiectomy; Prostate-Specific Antige | 1995 |
[Anti-androgen withdrawal syndrome].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Therapy; | 1998 |
2 trials available for flutamide and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Fre | 2008 |
Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androgen Antagonists; Cohort Studies; Flutamide; H | 1997 |
12 other studies available for flutamide and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flu | 2008 |
Effect of testosterone on morphine withdrawal syndrome in rats.
Topics: Androgen Antagonists; Androgens; Animals; Behavior, Animal; Female; Flutamide; Male; Morphine; Morph | 2008 |
Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Topics: Administration, Oral; Androgen Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents, Hor | 2010 |
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans | 2002 |
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; | 2004 |
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
Topics: Aged; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Orchiectomy; Prostate-Sp | 1993 |
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Topics: Aged; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate | 1993 |
[Fluamide withdrawal syndrome].
Topics: Adenocarcinoma; Aged; Flutamide; Humans; Male; Prostatic Neoplasms; Substance Withdrawal Syndrome | 1994 |
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Moda | 1995 |
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Neoplasms, Hormone-D | 1997 |
Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Topics: Androgen Antagonists; Flutamide; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Subst | 1997 |
Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brac | 1998 |